The chapter explores the development of a new form of MDMA for treating PTSD, examining the company involved, controversies, and challenges in clinical trials. It discusses the urgent need for solutions amidst the large number of PTSD sufferers, the therapy involved, and the FDA's review of this innovative treatment. The conversation also delves into the debate on the drug's effectiveness without the ecstatic experience, current limitations in PTSD treatments, and the investment landscape in biotech companies.
Watch Carol and Tim LIVE every day on YouTube: http://bit.ly/3vTiACF.
Bloomberg News Consumer Reporter Tiffany Kary discusses how almost forty years after it was banned, ecstasy is taking a big step toward becoming a licensed treatment for post traumatic stress disorder. Bloomberg Opinion Editor Mark Gongloff explains that persistent global heating makes it less likely that even a broad cooling weather pattern can halt the inexorable rise in temperatures. Bloomberg Intelligence Senior Semiconductor Analyst Kunjan Sobhani talks about Intel taking aim at Nvidia in the fight for AI chip dominance. And we Drive to the Close with Kathy Entwistle, Managing Director at Morgan Stanley Private Wealth Management.
Hosts: Carol Massar, Tim Stenovec and Emily Graffeo. Producer: Paul Brennan.
See omnystudio.com/listener for privacy information.